IBTK and infection: BTKi-containing regimens, either as monotherapy or combined with anti-CD20 or venetoclax, were not associated with a significantly increased risk of any infection compared to other regimens [BTKi + anti-CD20 or venetoclax: RR 0.93 (95% CI: 0.79–1.09, I2 = 46%), 3 trials; BTKi monotherapy: RR 1.12 (95% CI: 0.94–1.34, I2 = 73%), 3 trials].